Welcome to our dedicated page for INVO Fertility news (Ticker: IVF), a resource for investors and traders seeking the latest updates and insights on INVO Fertility stock.
INVO Fertility, Inc. (Nasdaq: IVF) generates news as a healthcare services fertility company focused on assisted reproductive technology (ART), clinic operations, and its INVOcell-enabled intravaginal culture (IVC) procedure. The news flow around IVF often reflects developments in its fertility clinic network, financing activities, and technology initiatives that support its mission to expand access to fertility care.
Investors and observers following IVF news can expect regular updates on clinic performance and growth, including revenue trends from its INVO Centers and IVF clinic, as well as commentary on organic growth drivers such as patient volume, telehealth expansion, and service offerings at locations like Wisconsin Fertility Institute. Earnings-related press releases have highlighted clinic revenue, product revenue from INVOcell, and adjusted EBITDA metrics, along with management’s narrative on operational progress.
Another key category of news involves acquisitions and strategic agreements. INVO Fertility has reported the acquisition of Wisconsin Fertility Institute and the signing of a definitive asset purchase agreement to acquire the non-clinical assets of Family Beginnings, a fertility clinic in Indiana, through its subsidiary INVO Centers LLC. Such announcements provide insight into the company’s efforts to build a broader network of fertility centers across the United States.
News items also cover capital markets and corporate actions, including private placements of common stock and warrants, registration statements on Form S-1 for resale of securities, and corporate actions such as the 1-for-8 reverse stock split effective November 28, 2025. These updates help investors understand changes in the company’s capital structure and financing arrangements.
Finally, technology and operational updates feature in IVF news, such as the partnership with Heidi Health to deploy an AI-powered scribe platform at Wisconsin Fertility Institute, telehealth launches, and patent developments for a modified INVOcell device. For a consolidated view of these developments, this news page offers a centralized feed of INVO Fertility’s latest press releases and related disclosures.
INVO Fertility (NASDAQ: IVF), a healthcare services company focused on expanding access to advanced fertility treatments, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference on May 29, 2025. The company will engage in a virtual webcast fireside chat at 4:15 p.m. ET and conduct one-on-one meetings with investors throughout the event.
The webcast will be accessible through the conference homepage and will be available for replay after the event. Investors interested in one-on-one meetings with management can arrange them through Lytham Partners or by registering for the event directly on their website.
INVO Fertility reported strong financial results for 2024, achieving a remarkable 116% annual revenue growth to $6.5 million. The company's Q4 2024 revenue reached $1.69 million, up 22% year-over-year.
Key highlights include a 125% increase in consolidated clinic revenue to $6.45 million and a 78% rise in total clinic revenue to $7.73 million. Despite these gains, the company recorded a net loss of $9.1 million, largely due to NAYA Therapeutics merger costs. However, Adjusted EBITDA improved significantly to $(2.2) million from $(4.9) million in 2023.
The company announced plans to divest its majority stake in NAYA Therapeutics to refocus on its core fertility operations. With three operating fertility centers in Wisconsin, Georgia, and Alabama, INVO aims to expand into additional markets, capitalizing on declining U.S. fertility rates and increasing demand for assisted reproductive technologies.